A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study on the Safety and Efficacy of Istaroxime for Pre-Cardiogenic Shock (SEISMiC)
Abstract
This is a pilot, multinational, randomized, double-blind, placebo-controlled, 2-part safety and efficacy study. Subjects will consist of patients hospitalized for acute decompensated heart failure with persistent hypotension.
Conditions: Cardiogenic Shock.
Primary outcome: Change from baseline in systolic blood pressure (SBP) area under the curve (AUC) 0-6.
Enrollment: 90 participants.
How strong is the evidence?
Evidence Hub reads this as a randomized trial, done in people. Its evidence level is 2 of 5 (High · randomized trial). Randomized trials of a reasonable size are the strongest single-study design. Reported size: 90 participants or records.
Read the paper
Related studies
- Current state and future directions for deep learning based automatic seismic fault interpretation: A systematic review
- Physics of Partially Saturated Porous Media: Residual Saturation and Seismic-Wave Propagation
- Modern Imaging Using Seismic Reflection Data
- Effects of marine seismic surveys on free-ranging fauna: a systematic literature review
- A review of the recent seismic activity in the southern part of egypt (upper egypt)
- A review of research on mechanism of seismic attenuation and energy compensation
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.